X

Drug Profile

Sodium cromoglicate - Nxera Pharma

Alternative Names: cromolyn sodium - Nxera Pharma

Latest Information Update: 02 Apr 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sosei Heptares
Developer Nxera Pharma
Class Analgesics
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Preclinical Pain

Most Recent Events

31 Mar 2024 Sosei Heptares is now called Nxera Pharma
03 Aug 2022 Preclinical trials in Pain in Japan (unspecified route) Before May 2022
01 Aug 2022 Sodium cromoglicate is available for licensing as of 01 Aug 2022. https://soseiheptares.com/our-pipeline/rd-pipeline/partnered-programs.html

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com